JB Chemicals Q3 Results: Profit Rises 22%, Declares Dividend Of Rs 8.50 Apiece
JB Chemicals & Pharmaceuticals' margin remained flat at 26.4% for the quarter under review.
JB Chemicals & Pharmaceuticals Ltd.'s consolidated net profit jumped 22% in the third quarter of the current financial year, meeting analysts' estimates.
It recorded a net profit of Rs 163 crore for the third quarter of the current financial year as compared to Rs 134 crore for the same period last fiscal.
The pharma firm's revenue grew 14% to Rs 963 crore for the three months ended Dec. 31, 2024, as against Rs 845 crore for the year-ago period. This compares to estimates of Rs 975 crore, tracked by Bloomberg.
The earnings before interest, tax, depreciation and amortisation surged to Rs 255 crore, denoting a 14% rise from Rs 223 crore for the same quarter of the corresponding year.
The margin remained flat at 26.4% for the quarter under review of the current fiscal.
JB Chemicals Q3 FY25 Highlights (Consolidated, YoY)
Net profit up 22% to Rs 163 crore versus Rs 134 crore. (Bloomberg estimate: Rs 159 crore)
Revenue up 14% to Rs 963 crore versus Rs 845 crore. (Bloomberg estimate: Rs 975 crore)
Ebitda up 14% at Rs 255 crore versus Rs 223 crore. (Bloomberg estimate: Rs 252 crore)
Margin flat at 26.4%. (Bloomberg estimate: 25.8%)
Dividend
The company has declared a dividend of Rs 8.50 per share at a face value of Rs 1 for financial year 2024–25.
The dividend will given to the shareholders on Feb. 21, 2025.
JB Chemicals Nine Months Earnings
In the first nine months of fiscal 2025, JB Chemicals posted a revenue of Rs 2,969 crore as against Rs 2,622, denoting a 13% growth. Its Ebitda rose to Rs 846 crore as compared to Rs 729 crore, representing a 16% surge.
From January to December, the company registered an increase in its profit from Rs 426 crore to Rs 514 crore, up 20%.
Ophthalmology portfolio from Novartis
After smooth integration in January 2024, the ophthalmology portfolio sales grew 30% to Rs 60 crore in the third quarter of fiscal 2025 versus Rs 46 crore in the fourth quarter of the financial year 2024 (first quarter since integration with JB Pharma) as per IQVIA data.
International Business
International business revenue increased 4% to Rs 397 crores. International formulations revenue decreased 4%. South Africa and branded generics exports grew, while US and Russia revenue declined.
CDMO business revenue grew 33% to Rs 118 crore. The Q4 FY25 order book is strong. API business revenue reached Rs 25 crores. Domestic and CDMO business revenue combined constitutes 70% of overall revenue for the nine months of fiscal 2025.
Shares of JB Chemicals closed 1.5% higher at 1,742.15 apiece on the National Stock Exchange, compared to a 1.62% rise in the benchmark Nifty. The stock has risen by 1.98% in the last 12 months.
